Diagnostics Drag and Debt Dilemma: Siemens Healthineers Stock Hovers Near Lows Ahead of Pivotal Investor Meeting

Diagnostics 'perfect storm' drags Siemens Healthineers stock near 52-week low despite solid Imaging, Therapy, and Varian growth. Strategic carve-out and €13.9B refinancing loom.

Siemens Healthineers heads into a high-stakes investor presentation in New York on Tuesday with the stock clinging to the edge of its 52-week low and a thicket of operational and financial challenges looming. The shares closed Friday at €33.59, barely above the trough of €33.50, and have lost about 24% since the start of the year.

The root cause is the Diagnostics division, which Chief Executive Bernd Montag has labelled a "perfect storm." In the second fiscal quarter, divisional revenue slid 6.5% on a comparable basis to €985 million, while the adjusted EBIT margin collapsed to just 0.9%. Weaker demand in China, falling reimbursement rates and rising costs have all converged to squeeze the unit. A deep restructuring is under way, but it is adding near-term pressure rather than relief.

Group-level numbers reflect the strain. Total revenue came in at €5.7 billion, representing comparable growth of only 3.1%. Adjusted earnings per share dropped to €0.53. Management has narrowed its full-year guidance, now targeting comparable revenue growth of 4.5% to 5.0% and adjusted EPS of €2.20 to €2.30.

The rest of the business, however, is performing solidly. Imaging grew 6.1%, beating market expectations; Precision Therapy advanced 4.7%; and the Varian oncology unit posted a 7.5% increase. Siemens Healthineers expects the combined Imaging and Precision Therapy portfolio to expand at an annual rate of 6% to 9% over the medium term. Yet these strengths have done little to lift the stock, as investors focus squarely on the Diagnostics mess.

The share is trading 21.52% below its 200-day moving average and well under the 50-day line, signalling that any recovery attempt has so far lacked conviction. Analysts have responded by trimming price targets. JPMorgan reduced its target to €55.80 but kept an "Overweight" rating; Bernstein lowered to €45.70 with an "Outperform"; and Goldman Sachs cut to €42.00, cautioning that a sustainable re-rating is unlikely until later in the year when progress on the planned Diagnostics carve-out becomes visible.

That carve-out is part of a broader strategic overhaul. Siemens Healthineers has formally initiated a process to spin off the Diagnostics business, and its parent Siemens intends to transfer 30% of its stake in the healthcare unit to Siemens shareholders. The necessary votes are scheduled for the respective annual general meetings in early 2027. Reuters has reported that Siemens aims to reduce its holding to below 20% over time, giving the subsidiary greater independence.

Independence, however, comes with a hefty price tag. Up to €13.9 billion in credit facilities currently guaranteed by Siemens will need to be refinanced in Healthineers' own name. Barclays estimates the additional interest expense for the current fiscal year at €74 million. The company's A3 rating from Moody's with a stable outlook provides some cushion, but the refinancing challenge adds uncertainty to an already complex equation.

Tariffs are another growing burden. Countermeasures have pushed costs from roughly €200 million in fiscal 2025 to an expected €400 million. Management has pledged to fully offset the impact by 2028, but for now the expense line is rising.

Net debt including pensions stood at €13.2 billion at the end of March, putting leverage at 3.1 times EBITDA. That ratio leaves limited headroom as the company juggles restructuring, refinancing and ordinary capital needs.

The next major checkpoint on the calendar is the third-quarter earnings release on July 31, 2026. Until then, investors will be looking for two things: clearer signs of a recovery in China's healthcare market and tangible progress on cost reduction in Diagnostics. Tuesday’s meeting in New York is unlikely to produce grand visions; rather, the market wants concrete answers on the Diagnostics turnaround, the refinancing plan and the tariff trajectory. How those questions are handled will determine whether the stock can finally break out of its slump.